领航医药生物科技配售协议失效

Group 1 - The company announced that the previously planned placement of up to 145 million shares at HKD 0.415 per share has become invalid [1] - The reason for the invalidation is that the conditions precedent of the agreement were not met by September 11, 2025 [1] - As a result, the placement will not proceed, and both the placement agent and the company have terminated their responsibilities under the agreement, with no claims allowed between the parties [1]